Medical device and methods of use for glaucoma treatment
The invention relates generally medical devices and methods for the treatment of glaucoma in an animal eye and, more particularly, to medical devices and methods for treating tissue of the trabecular meshwork and/or Schlemm's canal of the eye to restore or rejuvenate a portion or all of the normal physiological function of directing aqueous outflow for maintaining a normal intraocular pressure in the eye.
1. A method for treating tissue of trabecular meshwork of an eye by directing a liquid flow through the trabecular meshwork in an opposite direction of a physiological aqueous outflow pathway, the method comprising:
positioning a tubular member adjacent the trabecular meshwork of the eye;
applying suction to the trabecular meshwork through a lumen in said tubular member to cause fluid disposed in Schlemm's canal to be drawn from Schlemm's canal through the trabecular meshwork; and
aspirating the fluid drawn from Schlemm's canal through said tubular member.
2. The method of claim 1 , wherein the method further comprises providing an inflatable balloon disposed on a distal portion of said tubular member.
3. The method of claim 1 , wherein the method further comprises disposing fluid in Schlemm's canal through an elongate body with a portion of the elongate body being disposed in Schlemm's canal.
4. The method of claim 3 , wherein disposing fluid in Schlemm's canal comprises infusing a therapeutic agent from said elongate body.
5. The method of claim 4 , wherein the fluid comprises a sterile saline.
6. The method of claim 4 , wherein the fluid comprises a steroid.
7. The method of claim 4 , wherein the fluid comprises a growth factor.
8. The method of claim 4 , wherein the fluid comprises Imidazole antiproliferative agents.
9. The method of claim 4 , wherein the fluid comprises quinoxoalines.
10. The method of claim 4 , wherein the fluid comprises phosphonylmethoxyalkyl nucleotide analogs and related nucleotide analogs.
11. The method of claim 4 , wherein the fluid comprises potassium channel blockers.
12. The method of claim 4 , wherein the fluid comprises synthetic oligonucleotides.
13. The method of claim 4 , wherein the fluid comprises a Transforming Growth Factor-beta (TGF-beta).
14. The method of claim 4 , wherein the fluid comprises 5-[1-hydroxy-2-[2-(2-methoxyphenoxyl)ethylamino]ethyl]-2-methylbenzenesulfonamide.
15. The method of claim 4 , wherein the fluid comprises, wherein the therapeutic liquid comprises a pharmaceutical substance, the pharmaceutical substance being guanylate cyclase inhibitors.
16. The method of claim 4 , wherein the fluid comprises methylene blue, butylated hydroxyanisole, and N-methylhydroxylamine.
17. The method of claim 4 , wherein the fluid comprises 2-(4-methylaminobutoxy) diphenylmethane.
18. The method of claim 4 , wherein the fluid comprises apraclonidine and timolol.
19. The method of claim 4 , wherein the fluid comprises cloprostenol analogs or fluprostenol analogs.
20. The method of claim 4 , wherein the fluid comprises an ophthalmic composition that provides a sustained release of a water-soluble medicament, said water-soluble medicament comprising a crosslinked carboxy-containing polymer, a sugar, and water.
21. The method of claim 4 , wherein the fluid comprises a non-corneotoxic serine-threonine kinase inhibitor.
22. The method of claim 4 , wherein the fluid comprises a composition of non-steroidal glucocorticoid antagonist.
23. The method of claim 4 , wherein the fluid comprises a prostaglandin analog or a derivative thereof.